Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis
NCT03662126Phase 3Recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of navtemadlin in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (6 arms), sponsored by Kartos Therapeutics. Primary endpoint: Spleen Volume Reduction at 24 weeks. Started Jan 2019; status: recruiting.
02
Drugs
navtemadlin
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT03662126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662126.